View the mentioned paper here:
Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2839518
Access the mentioned course here:
Understanding Autism Spectrum Disorder: A Comprehensive Guide to Clinical Assessment & Diagnosis
https://psychscene.co/4zXOHNW
In this video, Dr Sanil Rege examines a 2025 randomised controlled trial of memantine for social impairment in young people with Autism Spectrum Disorder (ASD).
He explores whether memantine can improve social functioning and outlines how glutamatergic dysregulation, NMDA receptor modulation, and elevated anterior cingulate glutamate may help identify a biologically responsive subtype. He also considers how this may move the field beyond viewing autism as a single, uniform condition.
This session provides clinicians with a neurobiological framework for understanding autism through biomarkers, circuit dysfunction, and emerging precision psychiatry principles.
Chapters:
- Memantine for Social Impairment in Autism
- Why Autism May Not Be One Uniform Condition
- Trial Design and Participant Profile
- pGACC Glutamate as a Biomarker
- Response Rates and Subgroup Findings
- NMDA Receptors and Glutamatergic Mechanisms
- Memantine Versus Ketamine
- From Autism Spectrum to Neurobiological Subtypes
#Autism #Memantine #Psychiatry
What is Thinking In Psychiatry?
Thinking in Psychiatry is an Academy by Psych Scene podcast featuring short, high-signal audio episodes you can listen to on the go. Each week we break down emerging evidence, evolving clinical frameworks, and complex cases across the lifespan – from psychopharmacology and neurobiology to formulation, systems thinking, and metabolic and sleep psychiatry. Designed for busy clinicians, every episode is grounded in evidence, reviewed by faculty, and focused on one question: how can we practise better psychiatry, starting today?